Innovita Biological Technology Co. Ltd. A (688253) - Total Liabilities
Based on the latest financial reports, Innovita Biological Technology Co. Ltd. A (688253) has total liabilities worth CN¥136.00 Million CNY (≈ $19.90 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of Innovita Biological Technology Co. Ltd. to evaluate the company's liquid asset resilience ratio.
Innovita Biological Technology Co. Ltd. A - Total Liabilities Trend (2020–2025)
This chart illustrates how Innovita Biological Technology Co. Ltd. A's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Innovita Biological Technology Co. Ltd. balance sheet assets.
Innovita Biological Technology Co. Ltd. A Competitors by Total Liabilities
The table below lists competitors of Innovita Biological Technology Co. Ltd. A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
GRIPM Advanced Materials Co. Ltd. A
SHG:688456
|
China | CN¥1.07 Billion |
|
Xinjiang Tianye Co Ltd
SHG:600075
|
China | CN¥11.84 Billion |
|
Stepan Company
NYSE:SCL
|
USA | $1.19 Billion |
|
BioGaia AB (publ)
ST:BIOG-B
|
Sweden | Skr235.14 Million |
|
Shenzhen Sunline Tech Co Ltd
SHE:300348
|
China | CN¥960.72 Million |
|
Suzhou Shijia Science & Technology Inc
SHE:002796
|
China | CN¥629.19 Million |
|
Artivion Inc
NYSE:AORT
|
USA | $432.69 Million |
|
Aker Biomarine AS
OL:AKBM
|
Norway | Nkr237.50 Million |
Liability Composition Analysis (2020–2025)
This chart breaks down Innovita Biological Technology Co. Ltd. A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See how leveraged is Innovita Biological Technology Co. Ltd. 's balance sheet to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 15.58 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.06 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.06 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Innovita Biological Technology Co. Ltd. A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Innovita Biological Technology Co. Ltd. A (2020–2025)
The table below shows the annual total liabilities of Innovita Biological Technology Co. Ltd. A from 2020 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥223.32 Million ≈ $32.68 Million |
+1.94% |
| 2024-12-31 | CN¥219.07 Million ≈ $32.06 Million |
-2.05% |
| 2023-12-31 | CN¥223.65 Million ≈ $32.73 Million |
-11.69% |
| 2022-12-31 | CN¥253.24 Million ≈ $37.06 Million |
+324.16% |
| 2021-12-31 | CN¥59.70 Million ≈ $8.74 Million |
-47.67% |
| 2020-12-31 | CN¥114.08 Million ≈ $16.69 Million |
-- |
About Innovita Biological Technology Co. Ltd. A
Innovita Biological Technology Co., Ltd., a biopharmaceutical enterprise, engages in the research and development, production and sales of POCT rapid diagnostic products. It offers covid-19 test, respiratory disease test, gastrointestinal disease test, fertility test, tropical disease test, and hepatitis test. The company was founded in 2006 and is based in Beijing, China.